Harbor Capital Advisors Inc. Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Harbor Capital Advisors Inc. increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 79,648 shares of the company’s stock after acquiring an additional 2,180 shares during the period. Harbor Capital Advisors Inc. owned about 0.12% of MoonLake Immunotherapeutics worth $4,313,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MLTX. Barclays PLC raised its stake in shares of MoonLake Immunotherapeutics by 1,269.2% in the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after purchasing an additional 5,229 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its stake in MoonLake Immunotherapeutics by 55.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 20,325 shares of the company’s stock valued at $1,025,000 after acquiring an additional 7,247 shares during the period. State Street Corp boosted its holdings in shares of MoonLake Immunotherapeutics by 96.2% during the 3rd quarter. State Street Corp now owns 87,637 shares of the company’s stock valued at $4,419,000 after acquiring an additional 42,980 shares during the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of MoonLake Immunotherapeutics by 1.6% in the third quarter. Parkman Healthcare Partners LLC now owns 102,813 shares of the company’s stock worth $5,184,000 after acquiring an additional 1,589 shares during the period. Finally, HighVista Strategies LLC raised its holdings in shares of MoonLake Immunotherapeutics by 3.1% during the third quarter. HighVista Strategies LLC now owns 43,541 shares of the company’s stock valued at $2,195,000 after purchasing an additional 1,292 shares during the last quarter. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Stock Down 3.9 %

Shares of MLTX opened at $46.31 on Friday. The business has a 50-day simple moving average of $52.18 and a two-hundred day simple moving average of $48.80. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $64.98. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -35.90 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the prior year, the firm earned ($0.18) EPS. On average, equities analysts anticipate that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

MLTX has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday. Finally, Wedbush reissued an “outperform” rating and issued a $73.00 target price (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $81.43.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.